Blocking Translation of Oncogenic mRNA

Double-stranded RNA-mediated interference (RNAi), antisense oligonucleotides (ASO), and ribozymes have excellent specificity to their target oncogenic mRNA. They also seem show great promise when it comes treating cancer. The problem is that RNAi, ASO, poor stability are constantly being degraded by nucleases. Researchers made some efforts increase oligonucleotides’ creating phospharimidate Phosphorothioate. Currently, ribozymes, oligonucleotides, (RNAi) the three main methods used RNA. These currently undergoing clinical trials for purpose of focusing on specific RNAs involved in disorders like cancer neurodegeneration. In fact, ASOs amyotrophic lateral sclerosis spinal muscular atrophy produced promising results trials. formation chemical alterations boost affinity selectivity while reducing noxiousness owing off-target impacts two benefits ASOs. Another benefit increased affinity. With a focus RNAi ASOs, this review illustrated therapeutic strategies RNA therapy now use.